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invasion and angiogenesis of gastric cancer cells
through down-regulation of matrix
metalloproteinase 14
Liduan Zheng1,2†, Dan Li3†, Xuan Xiang3, Ling Tong1, Meng Qi3, Jiarui Pu3, Kai Huang2,4 and Qiangsong Tong2,3*Abstract
Background: Recent evidence indicates that methyl jasmonate (MJ), a plant stress hormone, exhibits anti-cancer
activity on human cancer cells. The aim of this study is to determine whether sub-cytotoxic MJ can abolish the
migration, invasion and angiogenesis gastric cancer cells.
Methods: Human gastric cancer cell lines SGC-7901 and MKN-45 were treated with diverse concentrations of MJ.
Cell viability, proliferation, migration, invasion and angiogenesis capabilities of cancer cells were measured by MTT
colorimetry, EdU incorporation, scratch assay, matrigel invasion assay, and tube formation assay. Gene expression
was detected by western blot and real-time quantitative RT-PCR. Binding of transcription factor on gene promoter
was detected by chromatin immunoprecipitation.
Results: Sub-cytotoxic (0.05 to 0.2 mM) MJ attenuated the migration, invasion and angiogenesis, but not the cell
viability or proliferation, of gastric cancer cells in a time- and dose-dependent manner, with down-regulation of
matrix metalloproteinase 14 (MMP-14) and its downstream gene vascular endothelial growth factor. Restoration of
MMP-14 expression rescued the SGC-7901 and MKN-45 cells from sub-cytotoxic MJ-inhibited migration, invasion
and angiogenesis. In addition, sub-cytotoxic MJ decreased the specificity protein 1 (Sp1) expression and binding on
MMP-14 promoter, while restoration of Sp1 expression rescued the cancer cells from sub-cytotoxic MJ-mediated
defects in MMP-14 expression, migration, invasion and angiogenesis.
Conclusions: Sub-cytotoxic MJ attenuates the MMP-14 expression via decreasing the Sp1 expression and binding
on MMP-14 promoter, thus inhibiting the migration, invasion and angiogenesis of gastric cancer cells.
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Gastric cancer is one of the most common cancers
worldwide [1]. In spite of the improvement of surgical
and multimodal therapy, invasion and metastasis of can-
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reproduction in any medium, provided the orrelated death, with a 5-year survival rate below 30% [2].
Chemotherapy is an appropriate option with the hope of
prolonged survival for gastric cancer patients [3]. Cur-
rently, over sixty percent of the anti-cancer agents in use
are derived from natural sources, including plants, mar-
ine organisms and micro-organisms [4]. Plant-derived
compounds, such as vinblastine, vincristine, topotecan,
irinotecan, etoposide and paclitaxel, have been an im-
portant source of clinically useful anti-cancer agents [5],
which possess therapeutic effects against cancer cells by
modulating cell cycle, proliferation, and viability [5].
Thus, novel anti-cancer plant-derived substances andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developed.
Plant stress hormones are natural bioregulators in
plant intracellular signaling and defense in response to
injury or environmental stresses, such as ultraviolet radi-
ation, osmotic shock and heat [6]. Among the plant hor-
mones, salicylic acid and its derivative aspirin are
extensively studied as potential anti-cancer therapeutics
and chemopreventive agents [6,7]. The jasmonate family,
a group of plant stress hormones consisting of cis-jas-
mone, jasmonic acid, and methyl jasmonate (MJ), are
fatty acid-derived cyclopentanones that occur ubiqui-
tously in the plant kingdom and regulate plant develop-
mental processes and adaptation to environment [8]. In
recent years, emerging evidence has shown the anti-
cancer effects of naturally occurring jasmonates and
their synthetic derivatives [9,10]. In general, MJ has been
found to be superior to cis-jasmone and jasmonic acid
in terms of cytotoxicity and induction of apoptosis in
human cancer cells [11,12], suggesting that MJ is a
promising agent for the development of cancer
therapeutics.
Our previous studies have demonstrated that MJ
exerts anti-tumor properties through down-regulating
the expression of proliferating cell nuclear antigen,
X-linked inhibitor of apoptosis protein, and survivin
[12,13]. We have also shown that cell permeable seven-
residue peptide of Smac significantly enhances the
growth inhibition effects of MJ on prostate cancer cells
[14]. However, the potential anti-cancer effects of MJ on
gastric cancer and the underlying mechanisms still re-
main largely unknown. In addition, most of the current
studies focus on the cytotoxicity of MJ on cancer cells,
while the effects of sub-cytotoxic MJ on the invasion,
metastasis and angiogenesis of cancer cells warrant fur-
ther investigation. In this study, we demonstrate, for the
first time, that sub-cytotoxic MJ suppresses the migra-
tion, invasion and angiogenesis of gastric cancer cells
through attenuating the expression of matrix metallo-
proteinase 14 (MMP-14) via decreasing the specificity




Human gastric cancer cell lines SGC-7901 (moderately
differentiated) and MKN-45 (poorly differentiated) were
obtained from the Type Culture Collection of Chinese
Academy of Sciences (Shanghai, China). Human endo-
thelial cell line HUVEC (CRL-1730) was purchased from
American Type Culture Collection (Rockville, MD). The
cells were grown in RPMI1640 medium (Life Technologies,
Inc., Gaithersburg, MD) supplemented with 10% fetal bo-
vine serum (Life Technologies, Inc.), penicillin (100 U/ml)and streptomycin (100 μg/ml). Cells were maintained at
37°C in a humidified atmosphere of 5% CO2. MJ (Sigma,
St Louis, MO) was prepared into stock solutions at a con-
centration of 1 mol/L in anhydrous dimethyl sulfoxide
(Sigma), and stored at −20°C. Confluent monolayers of
cells were incubated with different concentrations of MJ
for 6, 12 and 24 hrs as indicated. The 50% inhibitory con-
centration (IC50) of 24 hr exposure, defined as the drug
concentration resulting in 50% reduction of cell viability
compared to solvent control, was determined by Bliss’s
software (Bliss Co, CA).
Patient tissue samples
Approval to conduct this study was obtained from the
Institutional Review Board of Tongji Medical College (ap-
proval number: 2010-S003). Specimens of surgically
resected primary gastric carcinoma were collected from
twenty patients at the Department of Surgery, Union
Hospital of Tongji Medical College, Huazhong University
of Science and Technology in Wuhan, China. Their patho-
logical diagnosis was proven by at least two pathologists.
Adjacent gastric mucosa that contained no macroscopic
tumor was also obtained, and the non-neoplastic areas
were subsequently verified by microscopic histology to be
free of tumor infiltration. Fresh gastric cancer and non-
neoplastic tissues were collected and stored at −80°C until
use.
Measurement of cell viability
Cancer cells were cultured in 96-well plates at 5 × 103 cells
per well and treated with MJ or solvent. Cell viability was
monitored by the 2-(4,5-dimethyltriazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT, Sigma) colorimetric assay
[15]. All experiments were done with 6–8 wells per experi-
ment and repeated at least three times.
Cell proliferation assay
Cancer cells were cultured in 96-well plates at 5 × 103
cells per well, treated with MJ or solvent, and exposed to
50 μmol/L of 5-ethynyl-20-deoxyuridine (EdU, Ribobio,
China) for additional 4 hrs at 37°C. The cells were fixed
with 4% formaldehyde for 15 min and treated with 0.5%
Triton X-100 for 20 min at room temperature. After
washing with phosphate buffered saline (PBS) for three
times, the cells of each well were reacted with 100 μl of
1 × Apollo W reaction cocktail for 30 min. Subsequently,
the DNA contents of cells in each well were stained with
100 μl of Hoechst 33342 (5 μg/ml) for 30 min and visua-
lized under a fluorescent microscope.
Scratch migration assay
Cancer cells were cultured in 24-well plates, treated with
MJ or solvent, and scraped with the fine end of 1-ml
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Figure 1 (See legend on next page.)
Zheng et al. BMC Cancer 2013, 13:74 Page 3 of 13
http://www.biomedcentral.com/1471-2407/13/74
(See figure on previous page.)
Figure 1 Sub-cytotoxic MJ attenuated the migration, invasion and angiogenesis, but not the viabilities or proliferation, of gastric
cancer cells. Human gastric cancer cell lines SGC-7901 and MKN-45 were incubated with different concentrations of MJ as indicated. A, MTT
colorimetric assay indicated that MJ suppressed the cell viabilities of gastric cancer cells with a range of concentrations (0.5 to 2.0 mM), while
lower concentrations of MJ (0.05 to 0.2 mM) exerted no obvious cytotoxicity, when compared to those of solvent-treated (mock) cells. B, EdU
incorporation assay revealed that sub-cytotoxic MJ (0.05, 0.1 and 0.2 mM) did not attenuate the proliferation of SGC-7901 and MKN-45 cells, when
compared to that of mock cells. C, in scratch migration assay, administration of 0.05, 0.1 and 0.2 mM MJ attenuated the migration capabilities of
SGC-7901 and MKN-45 cells in a dose- and time-dependent manner, when compared to those of mock cells. D, transwell analysis indicated that
administration of sub-cytotoxic MJ (0.05, 0.1 and 0.2 mM) impaired the invasion capacities of SGC-7901 and MKN-45 cells in a dose- and
time-dependent manner, than those of mock cells. E, the tube formation of endothelial cells was dose- and time-dependently suppressed by the
medium preconditioned by treatment of gastric cancer cells with sub-cytotoxic MJ (0.05, 0.1 and 0.2 mM), than that of mock cells. The symbol (*)















































































































































































































































Figure 2 Sub-cytotoxic MJ down-regulated the expression of MMP-14 in gastric cancer cells. Human gastric cancer cell lines SGC-7901
and MKN-45 were incubated with sub-cytotoxic concentrations of MJ as indicated. A and B, western blot and real-time quantitative RT-PCR
indicated that administration of sub-cytotoxic (0.1 and 0.2 mM) MJ to SGC-7901 and MKN-45 cells for 24 hrs resulted in a decrease in the
expression of MMP-14, but not of MMP-7 or MMP-9, when compared to that of solvent-treated (mock) cells. C and D, western blot and real-time
quantitative RT-PCR indicated that administration of 0.2 mM MJ to SGC-7901 and MKN-45 cells for 6, 12, and 24 hrs, resulted in the decrease of
MMP-14 expression in a time-dependent manner, than that of mock cells. The symbol (*) indicates a significant decrease from mock.
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complete growth medium. Cell migration was photo-
graphed using 10 high-power fields, at 0 and 24 hrs
post-induction of injury. Remodeling was measured as
diminishing distance across the induced injury, normal-
ized to the 0 hr control, and expressed as outgrowth
(μm) [16].
Matrigel invasion assay
The Boyden chamber technique (transwell analysis) was
performed as previously described [16]. Cancer cells were
treated with MJ or solvent. Homogeneous single cell sus-
pensions (1 × 105 cells/well) were added to the upper
chambers, and allowed to invade for 24 hrs at 37°C in a
CO2 incubator. Migrated cells were stained with 0.1%
crystal violet for 10 min at room temperature and exam-
ined by light microscopy. Quantification of migrated cells
was performed according to published criteria [17].
Tube formation assay
Fifty microliters of growth factor-reduced matrigel were
polymerized on 96-well plates. HUVECs were serum
starved in RPMI1640 medium for 24 hrs, suspended in
RPMI1640 medium preconditioned with MJ- or solvent-
treated cancer cells, added to the matrigel-coated wells
at the density of 5 × 104 cells/well, and incubated at 37°C
for 18 hrs. Quantification of anti-angiogenic activity was
calculated by measuring the length of tube walls formed
between discrete endothelial cells in each well relative to
the solvent control [18].
Over-expression or knockdown of MMP-14 and Sp1
Human MMP-14 cDNA (1749 bp) expression construct
was established as previously described [16]. Human Sp1
cDNA (2358 bp) was amplified from cancer tissue and
subcloned into the Hind III and Xha I restrictive sites of
pcDNA3.1/Zeo(+) (Invitrogen) (Additional file 1: Table
S1). To restore the MJ-induced down-regulation of
MMP-14 or Sp1, cancer cells were transfected with the
recombinant vector pcDNA3.1-MMP14 or pcDNA3.1-
Sp1 for 72 hrs before administration of MJ or solvent.
The 21-nucleotide small interfering RNA (siRNA) tar-
geting the encoding region of MMP-14 was chemically
synthesized (RiboBio Co. Ltd; Additional file 1: Table S1)
and transfected with Genesilencer Transfection Reagent
(Genlantis, San Diego, CA). The scramble siRNA (si-
Scb) was applied as controls (Additional file 1: Table S1).
To monitor the transfection efficiency, the cancer
cells were co-transfected with pEGFP-N1 (Clontech,
Mountair View, CA).
Western blot
Tissue or cellular protein was extracted with 1 × cell
lysis buffer (Promega, Madison, WI). Western blot wasperformed as previously described [16,19], with anti-
bodies specific for matrix metalloproteinase 7 (MMP-7),
matrix metalloproteinase 9 (MMP-9), MMP-14, vascular
endothelial growth factor (VEGF), Sp1, and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA). Enhanced
chemiluminescence substrate kit (Amersham, Piscataway,
NJ) was used for the detection of signals with autoradiog-
raphy film (Amersham).
Real-time quantitative RT-PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen
Inc., Valencia, CA). The reverse transcription reactions
were conducted with Transcriptor First Strand cDNA
Synthesis Kit (Roche, Indianapolis, IN). The PCR
primers for MMP-7, MMP-9, MMP-14, VEGF, Sp1 and
β-actin were designed by Premier Primer 5.0 software
(Additional file 2: Table S2). Real-time quantitative RT-PCR
with SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) was performed as previously described
[16,19], using ABI Prism 7700 Sequence Detector (Applied
Biosystems). The fluorescent signals were collected during
extension phase, Ct values of the samples were calculated,
and the transcript levels were analyzed by 2-ΔΔCt method.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was
performed according to the manufacture’s instructions of
EZ-ChIP kit (Upstate Biotechnology, Temacula, CA) [19].
The PCR primers surrounding the MMP-14 transcription
start site were previously described [20]. Real-time quanti-
tative PCR (qPCR) with SYBR Green PCR Master Mix
was performed using ABI Prism 7700 Sequence Detector.
The amount of immunoprecipitated DNA was calculated
in reference to a standard curve and normalized to input
DNA.
Statistical analysis
Unless otherwise stated, all data were shown as mean ±
standard error of the mean (SEM). The SPSS 12.0 statis-
tical software (SPSS Inc., Chicago, IL) was applied for
statistical analysis. Pearson’s coefficient correlation was
applied for analyzing the relationship between Sp1 ex-
pression and MMP-14 transcript levels. Difference of
cancer cells was determined by t test or analysis of vari-
ance (ANOVA).
Results
Sub-cytotoxic MJ attenuated the migration, invasion and
angiogenesis of gastric cancer cells
Since previous studies imply the anti-metastatic and
anti-angiogenic properties of MJ [21,22], we hypothe-
sized that MJ might influence the migration, invasion
and angiogenesis of cultured gastric cancer cells. We

























































































































































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 Sub-cytotoxic MJ suppressed the expression of VEGF in gastric cancer cells. Human gastric cancer cell lines SGC-7901 and MKN-
45 were incubated with sub-cytotoxic concentrations of MJ as indicated. A and B, western blot and real-time quantitative RT-PCR indicated that
administration of sub-cytotoxic (0.1 and 0.2 mM) MJ to SGC-7901 and MKN-45 cells for 24 hrs resulted in a decrease in the expression of VEGF,
when compared to that of solvent-treated (mock) cells. C and D, western blot and real-time quantitative RT-PCR indicated that administration of
0.2 mM MJ to SGC-7901 and MKN-45 cells for 6, 12, and 24 hrs, resulted in the decrease of VEGF expression in a time-dependent manner, than
that of mock cells. E and F, 72 hrs post-transfection of MMP-14 expression vector into SGC-7901 and MKN-45 cells, western blot and real-time
quantitative RT-PCR indicated the over-expressed MMP-14 and VEGF than that of empty vector-transfected (mock) cells. G and H, 24 hrs post-
transfection of si-MMP14 (100 nmol/L) into SGC-7901 and MKN-45 cells, western blot and real-time quantitative RT-PCR indicated the down-
regulated MMP-14 and VEGF than those transfected with scramble siRNA (si-Scb, 100 nmol/L). The symbols (* and △) indicate a significant
decrease and a significant increase from mock or si-Scb, respectively.
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cells. As shown in Figure 1A, MJ suppressed the cell
viabilities of gastric cancer cells with a range of concen-
trations (0.5 to 2.0 mM), while lower concentrations of
MJ (0.05 to 0.2 mM) exerted no obvious cytotoxicity.
The IC50 of MJ on SGC-7901 and MKN-45 cells were
1.72 and 1.24 mM, respectively. EdU incorporation assay
was applied to further study the influence of sub-
cytotoxic MJ on the proliferation of gastric cancer cells.
As shown in Figure 1B and Additional file 3: Figure S1,
administration of sub-cytotoxic (0.05, 0.1 and 0.2 mM)
MJ did not attenuate the cell viabilities or proliferation.
In scratch migration assay, sub-cytotoxic MJ attenuated
the migration capabilities of SGC-7901 and MKN-45
cells in a dose- and time-dependent manner (Figure 1C).
Transwell analysis showed that gastric cancer cells trea-
ted with sub-cytotoxic (0.05, 0.1 and 0.2 mM) MJ pre-
sented a dose- and time-dependently impaired invasion
capacity than solvent-treated (mock) cells (Figure 1D).
The tube formation of endothelial cells was dose- and
time-dependently suppressed by the medium precondi-
tioned by treatment of gastric cancer cells with 0.05, 0.1
and 0.2 mM MJ (Figure 1E). However, the proliferation
of endothelial HUVEC cells was not affected by sub-
cytotoxic MJ (Additional file 4: Figure S2), ruling out the
possibility that sub-cytotoxic MJ affected the angiogen-
esis through direct cytotoxicity on endothelial cells.
These results indicated that sub-cytotoxic MJ attenuated
the migration, invasion and angiogenesis of gastric can-
cer cells in vitro.
Sub-cytotoxic MJ down-regulated the expression of MMP-
14, but not of MMP-7 and MMP-9, in gastric cancer cells
Since previous studies reveal the critical roles of MMP-7,
MMP-9 and MMP-14 in the invasion and metastasis of
gastric cancer [23], we hypothesized that MJ might influ-
ence the expression of these genes. Western blot indicated
that administration of sub-cytotoxic (0.1 and 0.2 mM) MJ
resulted in a decrease in the expression of MMP-14, but
not of MMP-7 or MMP-9, in cultured gastric cancer
SGC-7901 and MKN-45 cells (Figure 2A). Real-time
quantitative RT-PCR revealed the decreased transcript
levels of MMP-14, but not of MMP-7 or MMP-9, ingastric cancer cells treated with sub-cytotoxic MJ
(Figure 2B). In addition, sub-cytotoxic MJ-mediated inhib-
ition on MMP-14 expression was in a time-dependent
manner (Figure 2C and D). These results indicated that
sub-cytotoxic MJ suppressed the MMP-14 expression in
gastric cancer cells.
Sub-cytotoxic MJ suppressed the expression of VEGF in
gastric cancer cells
Since previous studies indicate that MMP-14 can regulate
the VEGF expression in breast cancer cells [24], and com-
bining the evidence that VEGF participates in the angio-
genesis [25], we hypothesized that sub-cytotoxic MJ might
also influence the expression of VEGF in gastric cancer
cells. Western blot and real-time quantitative RT-PCR
indicated that administration of sub-cytotoxic (0.1 and 0.2
mM) MJ resulted in a significant decrease of VEGF ex-
pression in gastric cancer SGC-7901 and MKN-45 cells,
which was consistent with MMP-14 reduction (Figure 3A
and B). In addition, sub-cytotoxic MJ-mediated inhibition
on VEGF expression was in a time-dependent manner
(Figure 3C and D). Furthermore, over-expression or
knockdown of MMP-14 promoted or suppressed the
VEGF expression in gastric cancer cells, respectively
(Figure 3E, F, G and H), suggesting that as a direct down-
stream gene of MMP-14, the change of VEGF expression
in sub-cytotoxic MJ-treated cancer cells may be due to the
down-regulation of MMP-14.
Over-expression of MMP-14 rescued sub-cytotoxic MJ-
mediated suppression on VEGF expression, migration,
invasion and angiogenesis of gastric cancer cells
To further investigate the role of MMP-14 down-regula-
tion in MJ-induced decrease in the migration, invasion and
angiogenesis, MMP-14 expression construct was trans-
fected into gastric cancer cells. The transfection efficiency
was monitored by co-transfection with the enhanced green
fluorescent protein (EGFP) reporter vector. Seventy-two
hrs post-transfection, EGFP expressed within the cyto-
plasm of cancer cells, with the transfection efficiency
around 60% (Additional file 5: Figure S3). As shown in
Figure 4A and B, transfection of SGC-7901 and MKN-45
cells with MMP-14 construct restored the sub-cytotoxic
Zheng et al. BMC Cancer 2013, 13:74 Page 8 of 13
http://www.biomedcentral.com/1471-2407/13/74MJ-attenuated expression of MMP-14 and VEGF. Restor-
ation of MMP-14 expression rescued the SGC-7901 and
MKN-45 cells from their defects in migration, invasion,
and angiogenesis induced by sub-cytotoxic (0.2 mM) MJ
(Figure 4C, D, and E). These results suggested that sub-
cytotoxic MJ-induced suppression of migration, invasion
and angiogenesis of gastric cancer cells, at least in part,




























































































































































































Figure 4 Restoration of MMP-14 rescued sub-cytotoxic MJ-mediated
angiogenesis of gastric cancer cells. Human gastric cancer cell lines SGC
72 hrs, and incubated with sub-cytotoxic MJ for 24 hrs. A and B, western b
SGC-7901 and MKN-45 cells with MMP-14 construct rescued the MJ-attenu
transfected with empty vector (mock) and treated with solvent. C, in scratc
of SGC-7901 and MKN-45 cells, and rescued the 0.2 mM MJ-induced inhibi
solvent-treated mock cells. D, transwell analysis indicated that restoration o
mM MJ-induced suppression of invasiveness, when compared to that of so
SGC-7901 and MKN-45 cells rescued the 0.2 mM MJ-induced suppression o
The symbols (* and △) indicate a significant decrease and a significant incrSub-cytotoxic MJ suppressed the expression and binding
of Sp1 on MMP-14 promoter
Previous studies have revealed the critical role of tran-
scription factor Sp1 in the regulation of MMP-14 ex-
pression in cancer cells [20]. To further explore the
underlying mechanism for sub-cytotoxic MJ-induced
MMP-14 down-regulation, cancerous and adjacent non-
neoplastic tissues from twenty gastric cancer patients








































































































































































suppression on VEGF expression, migration, invasion and
-7901 and MKN-45 were transfected by MMP-14 expression vector for
lot and real-time quantitative RT-PCR indicated that transfection of
ated expression of MMP-14 and VEGF, when compared to those
h migration assay, over-expression of MMP-14 promoted the migration
tion on the migration of cancer cells, when compared to that of
f MMP-14 expression rescued the SGC-7901 and MKN-45 cells from 0.2
lvent-treated mock cells. E, restoration of MMP-14 expression in
f angiogenesis, when compared to that of solvent-treated mock cells.










































































































































































































































Figure 5 Sub-cytotoxic MJ suppressed the Sp1 expression and binding on MMP-14 promoter in gastric cancer cells. A and B, cancerous
(C) and adjacent non-neoplastic (N) tissues from twenty gastric cancer patients were collected for the analysis of Sp1, MMP-14, and VEGF
expression. Western blot and real-time quantitative RT-PCR indicated that the expression of Sp1, MMP-14, and VEGF was significantly higher in
gastric cancer tissues than that of adjacent neoplastic tissues. C, Pearson’s coefficient correlation analysis demonstrated a positive correlation
between Sp1 protein and MMP-14 transcript levels in gastric cancer tissues (r = 0.917, P < 0.001). D and E, western blot and real-time quantitative
RT-PCR indicated that administration of 0.1 and 0.2 mM MJ to SGC-7901 and MKN-45 cells for 24 hrs, resulted in decreased Sp1 expression than
that of solvent-treated (mock) cells. F, ChIP assay and real-time quantitative PCR indicated that administration of 0.1 and 0.2 mM MJ to SGC-7901
and MKN-45 cells for 24 hrs, resulted in decreased Sp1 binding on MMP-14 promoter than that of mock cells. There were no PCR products for
“no-antibody” (No Ab) control. The symbols (* and △) indicate a significant decrease and a significant increase from adjacent tissues or
mock, respectively.
Zheng et al. BMC Cancer 2013, 13:74 Page 9 of 13
http://www.biomedcentral.com/1471-2407/13/74
Zheng et al. BMC Cancer 2013, 13:74 Page 10 of 13
http://www.biomedcentral.com/1471-2407/13/74RT-PCR indicated that the expression of Sp1, MMP-14,
and VEGF was significantly higher in gastric cancer tissues
than that of adjacent non-neoplastic tissues (Figure 5A
and B). Importantly, there was a positive correlation be-
tween Sp1 protein and MMP-14 transcript levels in gastric
cancer tissues (Figure 5C). Administration of sub-
cytotoxic (0.1 and 0.2 mM) MJ resulted in a decrease in
the Sp1 expression in gastric cancer SGC-7901 and MKN-
45 cells (Figure 5D and E). ChIP assay further revealed the
decreased binding of Sp1 on MMP-14 promoter in cancer
cells treated with sub-cytotoxic MJ (Figure 5F). These
findings indicated that sub-cytotoxic MJ attenuated the
MMP-14 expression via decreasing the Sp1 expression
and binding on MMP-14 promoter in gastric cancer cells.
Restoration of Sp1 rescued sub-cytotoxic MJ-mediated
suppression on MMP-14 expression, migration, invasion
and angiogenesis of gastric cancer cells
Since above evidence showed that Sp1 participated in the
transcriptional regulation of MMP-14 in gastric cancer, we
proposed that Sp1 might play an important role in sub-
cytotoxic MJ-induced decrease in the migration, invasion
and angiogenesis of gastric cancer cells. Human Sp1 ex-
pression construct was established and transfected into
cancer cells. As shown in Figure 6A and B, transfection of
SGC-7901 and MKN-45 cells with Sp1 construct rescued
the sub-cytotoxic MJ-attenuated MMP-14 expression.
Restoration of Sp1 into SGC-7901 and MKN-45 cell
lines rescued the decrease in migration, invasion, and
angiogenesis induced by sub-cytotoxic (0.2 mM) MJ
(Figure 6C, D, and E). These results suggested that sub-
cytotoxic MJ-induced decrease in Sp1 expression contrib-
uted to down-regulation of MMP-14 and suppression of
migration, invasion and angiogenesis of gastric cancer
cells.
Discussion
In 2002, Fingrut et al. first reported the jasmonates-
mediated suppression of cellular proliferation and induc-
tion of cell death in various human and mouse cancer
cell lines, including breast cancer, prostate cancer, mel-
anoma, lymphoblastic leukemia, and lymphoma [6]. In
the past decade, several groups have demonstrated that
members of jasmonate family and their synthetic deriva-
tives exhibit anti-cancer activity on other kinds of tumor
cells, including lung cancer [26], colon cancer [27], gli-
oma [28], cervical cancer [29,30], neuroblastoma [12,13],
and myeloid leukemia [31,32]. To date, several mechan-
isms have been proposed to explain the anti-cancer
effects of jasmonates, including induction of severe ATP
depletion via mitochondrial perturbation [33], induction
of re-differentiation via mitogen-activated protein kinase
activity [31], induction of a significant decrease in survi-
vin levels via the β-catenin/T-cell factor pathway [27],and induction of apoptosis via pro-apoptotic proteins of
the Bcl-2 family [34], opening the mitochondrial perme-
ability transition pore complex [11] and activation of ex-
trinsic apoptotic pathway [35]. However, the anti-cancer
activity of sub-cytotoxic jasmonates and underlying
mechanisms still warrant further investigation.
Recent evidence shows that MJ can inhibit melanoma
cell migration and suppress the development of melan-
oma growth in mouse lungs [21], suggesting the poten-
tial anti-metastatic activities of MJ. In the current study,
we demonstrated that in addition to the cytotoxic prop-
erties of MJ in cancer therapy, sub-cytotoxic MJ attenu-
ated the migration and invasion of human gastric cancer
SGC-7901 and MKN-45 cells. The SGC-7901 cell line
was first established from the metastatic lymph node of
a 56-year-old female patient suffering from gastric
adenocarcinoma [36], while the MKN-45 cell line was
derived from a metastatic liver tumor of a 62-year-old
female with gastric cancer [37]. It is well known that the
extracellular matrix (ECM) is a barrier to prevent tumor
cells from invasion and metastasis [38]. Specific enzymes
produced by cancer cells and activated by certain signals,
such as matrix metalloproteinases (MMPs), have been
reported to degrade ECM, and are associated with the
progression of gastric cancer [23,39]. MMP-14, also
named as membrane type-1 matrix metalloproteinase,
functions as a pericellular collagenase and plays an im-
portant role in tumor invasion and metastasis by facili-
tating the cancer cells to remodel and penetrate ECM
[40-42]. Clinical evidence has shown the linkage between
high MMP-14 expression and cancer progression, such
as lymph node metastases, invasion, poor clinical stage,
larger tumor size, and increasing tumor stage [43]. In
this study, we found that sub-cytotoxic MJ selectively
down-regulated the expression of MMP-14, but not of
MMP-7 and MMP-9, in gastric cancer cells. In addition,
restoration of MMP-14 rescued the sub-cytotoxic MJ-
induced inhibition on the migration and invasion of cancer
cells, suggesting the role of MMP-14 down-regulation in
the anti-metastatic activities of sub-cytotoxic MJ.
Since MMP-14-mediated degradation of ECM occurs
throughout the angiogenic process and contributes to
vascular regression [41], we further demonstrated that
sub-cytotoxic MJ attenuated the angiogenic capabilities of
gastric cancer cells. In addition, sub-cytotoxic MJ did not
induce the cell death of human umbilical vein endothelial
cells, ruling out the influence of direct cytotoxicity on
angiogenesis. In a previous study, MJ was noted to consist-
ently impair the vascular growth in the Chorioallantoic
model of angiogenesis [22], while the underlying mechan-
isms remain largely unknown. VEGF, a dimeric and
heparin-binding glycoprotein that functions as a potent
mitogen of vascular endothelial cells, is a major inducer of
angiogenesis that can promote the growth and metastasis
Zheng et al. BMC Cancer 2013, 13:74 Page 11 of 13
http://www.biomedcentral.com/1471-2407/13/74of tumors [25]. In this study, for the first time, we demon-
strate that VEGF functions as a downstream gene of
MMP-14 in gastric cancer cells. Since our findings indi-
cated that sub-cytotoxic MJ abolished the VEGF expres-
sion in gastric cancer cells, combining the evidence that
restoration of VEGF expression through MMP-14 over-
expression rescued the decrease in tube formation of
endothelial cells, we believe that the decreased expression
















































































































































































Figure 6 Restoration of Sp1 rescued sub-cytotoxic MJ-mediated supp
angiogenesis of gastric cancer cells. Human gastric cancer cell lines SGC
hrs, and incubated with sub-cytotoxic MJ for 24 hrs. A and B, western blot
SGC-7901 and MKN-45 cells with Sp1 construct rescued the MJ-attenuated
with empty vector (mock) and treated with solvent. C, in scratch migration
and MKN-45 cells, and rescued the 0.2 mM MJ-induced inhibition on the m
mock cells. D, transwell analysis indicated that restoration of Sp1 expression
SGC-7901 and MKN-45 cells, when compared to that of solvent-treated mo
rescued the 0.2 mM MJ-induced suppression of angiogenesis, when comp
indicate a significant decrease and a significant increase from solvent-treatecontributes to the anti-angiogenic function of sub-
cytotoxic MJ in gastric cancer cells.
To elucidate the mechanisms underlying the down-
regulation of MMP-14 by sub-cytotoxic MJ, we further
demonstrated that the MMP-14 transcript levels were
abolished in MJ-treated gastric cancer cells. Because of
the lack of typical TATA box and the presence of a GC-
rich sequence immediately upstream of the transcrip-


























































































































































ression on MMP-14 expression, migration, invasion and
-7901 and MKN-45 were transfected by Sp1 expression vector for 72
and real-time quantitative RT-PCR indicated that transfection of
expression of Sp1 and MMP-14, when compared to those transfected
assay, over-expression of Sp1 promoted the migration of SGC-7901
igration of cancer cells, when compared to that of solvent-treated
rescued the 0.2 mM MJ-induced inhibition on the invasiveness of
ck cells. E, restoration of Sp1 expression in SGC-7901 and MKN-45 cells
ared to that of solvent-treated mock cells. The symbols (* and △)
d mock cells, respectively.
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http://www.biomedcentral.com/1471-2407/13/74control of MMP-14 is unique compared to other MMP
family members [44]. The GC-rich region within human
MMP-14 promoter serves as the putative binding site
for transcription factor Sp1 in fibrosarcoma and prostate
cancer cells [20,44]. In addition, constitutive Sp1 binding
to the MMP-14 promoter was also noted in rat glomeru-
lar mesangial cells [45]. In this study, we demonstrated
the over-expressed Sp1 and its positive correlation with
MMP-14 transcription in gastric cancer tissues. Then, we
sought to determine whether Sp1 played a role in regulat-
ing MMP-14 in gastric cancer cells. Electrophoretic mobil-
ity shift assay is a traditional method to investigate the
transcription factor-DNA interaction via studying the
binding of protein to known DNA oligonucleotide probes
[46]. However, this method is an in vitro assay and rela-
tively difficult to be quantified [46]. In recent years, ChIP
assay is an alternative method to monitor transcriptional
regulation through transcription factor-DNA binding
interaction in living cells, which is quantitative when
coupled with qPCR analysis [46]. Here, we showed that
Sp1 bound to the MMP-14 promoter in gastric cancer
cells via ChIP assay. Additionally, administration of sub-
cytotoxic MJ attenuated the Sp1 expression and binding
to MMP-14 promoter, implying the important role of Sp1
in sub-cytotoxic MJ-induced down-regulation of MMP-14
in gastric cancer cells.
Conclusions
In summary, we demonstrate, for the first time, that sub-
cytotoxic MJ attenuates the MMP-14 expression via
decreasing the Sp1 expression and binding on MMP-14
promoter, thus inhibiting the migration, invasion and
angiogenesis of gastric cancer cells. These findings support
the notion that in addition to its cytotoxic activity, sub-
cytotoxic MJ exerts anti-metastatic and anti-angiogenic
functions as well. These results lay the groundwork for
further investigation into the mechanisms of MJ-mediated
anti-cancer functions, which is of potential values as a
novel therapeutic approach for gastric cancer.Additional files
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and small interfering RNAs.
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Additional file 3: Figure S1. Time-course effects of
sub-cytotoxic MJ on the viability of gastric cancer cells. Human gastric
cancer SGC-7901 and MKN-45 cells were incubated with sub-cytotoxic
(0.05, 0.1 and 0.2 mM) MJ for 6, 12 and 24 hrs. MTT colorimetric assay
indicated that sub-cytotoxic MJ did not affect the viabilities of gastric
cancer cells, when compared to those treated by solvent (mock).
Additional file 4: Figure S2. Sub-cytotoxic MJ did not affect the
proliferation of human endothelial cells. Human endothelial HUVEC cells
were incubated with sub-cytotoxic (0.05, 0.1 and 0.2 mM) MJ for 24 hrs.
EdU incorporation assay indicated that sub-cytotoxic MJ did not affectthe proliferation of HUVEC cells, when compared to those treated by
solvent (mock).
Additional file 5: Figure S3. Transfection efficiency assay. Confluent
monolayers of gastric cancer SGC-7901 and MKN-45 cells were
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